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Abstract
Background: In 2000, the national cancer plan for England created 34 cancer networks, new
organisational structures to coordinate services across populations varying between a half and
three million people. We investigated the availability of data sets reflecting measures of structure,
process and outcome that could be used to support network management.
Methods: We investigated the properties of national data sets relating to four common cancers
– breast, colorectal, lung and prostate. We reviewed the availability and completeness of these data
sets, identified leading items within each set and put them into tables of the 34 cancer networks.
We also investigated methods of presentation.
Results: The Acute Hospitals Portfolio and the Cancer Standards Peer Review recorded structural
characteristics at hospital and cancer service level. Process measures included Hospital Episode
Statistics, recording admissions, and Hospital Waiting-List data. Patient outcome measures included
the National Survey of Patient Satisfaction for cancer, and cancer survival, drawn from cancer
registration. Data were drawn together to provide an exemplar indicator set a single network, and
methods of graphical presentation were considered.
Conclusion: While not as yet used together in practice, comparative indicators are available
within the National Health Service in England for use in performance assessment by cancer
networks.
Background
"Assessment of the quality of cancer treatment and care
depends upon the availability of accurate and relevant
information about the process and outcomes of care for
patients [1]."
Cancer is a leading cause of death and disability across the
world, and cancer services consume a significant propor-
tion of health care resources. In England, the Calman-
Hine report [2] in 1995 prioritised improvement in the
quality of cancer services up to international levels, and
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the English Department of Health developed a 'National
Service Framework' for cancer. This Cancer Plan [3] led to
appointment of a national Director of Cancer Services and
national Cancer Action Team, responsible for implemen-
tation, a Cancer Services Collaborative tasked with
improving hospital-level organization of services, a new
managerial tier of 34 cancer networks to coordinate serv-
ices between hospitals, and development of local tumour-
specific multi-disciplinary teams to provide enhanced
specialist care.
Cancer networks in England were chosen to reflect exist-
ing geographical patterns of referral and joint care for can-
cer patients, for example for radiotherapy and specialised
surgery or chemotherapy. They cover populations varying
between a half and 3 million people, and roughly follow-
ing local administrative boundaries. They each have a
small administrative team of 5–15 staff, some of whom
are centrally funded and thereby accountable to the Can-
cer Action Team. Network members are determined
locally, drawing together managerial staff from NHS hos-
pitals and clinical staff collaborating in tumour-specific
multi-disciplinary teams.
To underpin the Government's commitment to improv-
ing the quality of cancer services and modernising cancer
care, the Director of Cancer Services issued a Cancer Infor-
mation Strategy [4] designed to monitor progress towards
achieving specific targets (such as waiting times) and
reducing the cancer death rate. The Strategy recom-
mended that '...cancer networks should develop appropri-
ate structures and processes to improve the availability
and quality of information for cancer patients and carers';
and that 'monitoring of performance indicators which
relate to the quality of cancer services delivery, including
screening, should form part of the assessment of individ-
ual cancer services.' The Strategy concluded that 'Health
service managers and commissioners working at local ...,
regional or national level will need information on the
structure, process and outcome of cancer care in the area
for which they are responsible.' This required 'informa-
tion about cancer services and aggregated information on
activity and outcomes.'
As part of a study to measure quality in cancer services [5],
we have identified a set of relevant indicators that could
be derived from existing data sources, and that could be
used as performance measures by cancer networks. We
report on the data sources and the availability, character-
istics and presentation of these data sets.
Methods
Donabedian [6] recommended analysis of health services
according to structure (the resources and facilities for serv-
ices), process (the activity of providing services) and out-
come (the effect on the patient or population). Mainz [7]
has also used this typology in reviewing use of clinical
indicators for quality in health care. We identified
national data sets from public sources – NHS, government
agencies, and Department (Ministry) of Health – that
related to one or more of these three elements, and were
granted access the data sets by their primary owners. We
investigated availability of data that had supported the
Audit Commission Report on Cancer Services in England
and Wales [8], but decided not to use this as the survey
covered less than a quarter of the country. We gained data
collected on palliative care services by a national charity,
but we also decided not to use this as only some services
had contributed data and the denominator populations
were unknown.
Black et al [9] describe development of the Directory of
Clinical Databases (DoCDat), an archive describing over
150 clinical databases in the UK. Fields recorded include
general aspects (when it was set up, who it includes, geo-
graphical area it covers), data set (individuals and items
included, security and confidentiality), outputs (who can
analyse the data, audit reports, publications), manage-
ment (who runs the data base, funding), quality of the
data (aspects of coverage and accuracy) and contact
details. Two of our six data sets were already recorded in
DoCDat (for their national use) – cancer registration and
Hospital Episode Statistics. We drew reports for these two
from DoCDat, and used the format for assessing the other
four data sets.
We requested, where appropriate, only data for four can-
cers – breast, colo-rectal, lung, prostate. One data set – the
English Healthcare Commission's Acute Hospital Portfo-
lio [10] – does not identify cancer patients or services sep-
arately, but included data on hospital structures that are
relevant. We assessed the completeness of the data,
excluding variables where incompleteness was a signifi-
cant problem, (usually more than 10%). For some data
sets, data were missing either as individual items or for the
hospital as a whole. We made numerical checks to con-
firm that each variable's data were within appropriate
ranges. We looked at distributions to determine outliers
and, where data were normally distributed, calculated 5%
confidence limits.
Results
Six data sets forming the 'Cancer Networks Limited Data
Set' are described. The Tables present the indicators for
each data set, but only for one cancer each (for brevity).
Acute Hospital Portfolio
Information about health services in England were col-
lected by the Audit Commission from 2000/01, and have
been continued thereafter annually by the HealthcareBMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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Commission [10]. Each survey addresses a different aspect
of healthcare provision, including financial, facilities,
structural and personnel. In the period for our study, we
identified four relevant sets: medical staffing, ward statis-
tics, radiology and medicines management. The 1999/
2000 and 2000/2001 surveys were made on 188 NHS
acute hospital trusts. There were explicit rules for deciding
how to record variables, and data sets were estimated as
mostly more than 80% complete. We chose a small
number of relevant indicators from each set (Tables 1, 2,
3, 4).
Cancer Services Peer Review
Along with the NHS Cancer Plan for England, a Manual
for Cancer Services Standards was developed by the
Department of Health. Approximately 170 hospital can-
cer units and centres were asked to assess themselves
against these standards, and were then visited by teams of
health care professionals and managers with expertise in
the day-to-day delivery of cancer care, and also patient
representatives. The visits were organised by each of the
13 NHS regions, and data collected uniformly (except for
one region, Trent, which had piloted a different instru-
ment). The review teams assessed the presence or absence
of over 180 variables grouped in 10 areas: patient centred
care, multi-disciplinary teams (for breast, colo-rectal and
lung cancers), diagnostic services, oncology, radiotherapy,
chemotherapy, palliative care, training, communication,
and organisation. Through the detailed recording meth-
ods, all variables were at least 95% complete. For the Can-
cer Networks Limited Data Set, standards were selected in
two areas:
￿ Compliance with all cancer standards for each main
theme area – 12 variables (Table 5).
￿ Compliance with multi-disciplinary team (MDT) theme
variables (cancer-specific), grouped according to the sub-
themes specified within the Manual – for breast 11 varia-
bles, (Table 6), colorectal 10 variables, and lung 10 varia-
bles.
Hospital Episode Statistics
These data are collected routinely in all NHS hospitals and
units, and record more than 12 million in-patient epi-
sodes per year. Data are held electronically by the NHS
Health and Social Care Information Centre, a not-for-
profit agency run by the National Health Service. Within
a large data set, in which episodes can be linked within-
year (but not across years), data were chosen for patients
with a cancer diagnosis and data on length of admission
by hospital, operation and consultant specialty (Table 7).
Definitions of variables held are in the HES Data Diction-
ary. A national study in 2002 indicated 99% coverage of
admissions [9], but for the variable 'mean and median
length of stay' in the Limited Data Set, missing data by
diagnosis was: breast 9.3%, colo-rectal 5.7%, lung 13.3%,
prostate 6.5%.
Cancer Waiting Times
These data are collected by all NHS acute hospital trusts in
England. For each trust, the data recorded in 2001/2002
were the percentage of GP urgent referrals achieving a
waiting time of less than or equal 2 weeks (by tumour type
– one month for some rarer cancers). However, measuring
patients referred with a possible cancer diagnosis both
includes non-cancer patients (wrong initial diagnosis)
and excludes those identified by other routes (about half
of all cancers). There are clear definitions and coding
rules, but local completeness is unassessed, and data are
missing for some trusts. The data are reported quarterly
[11]. Table 8 shows returns for three years for lower gas-
tro-intestinal cancer (ICD-10 codes C17-21 and C26,
including malignant neoplasms of small intestine, colon,
rectum, anus, and other and ill-defined digestive organs).
Cancer survival
The 9 regional cancer registries in England collect popula-
tion-based data on incidence and mortality from cancer.
A subset of the data collected by the regional cancer regis-
tries is collated centrally to provide national figures on
cancer incidence and survival. Regional cancer registries
receive notification of incident cancer cases from sources
Table 1: Acute Hospital Portfolio indicators for hospitals in the network: Medical Staffing
Hospitals
Indicators A B C D E F G
Consultant WTE* per 1000 all admissions 2.12 5.45 2.04 n/a 2.31 2.26 n/a
Anaesthetist Consultant WTE per 1000 surgical admissions 0.85 1.79 1.01 n/a 0.83 1.31 n/a
Medicine Consultant WTE per 1000 medicine admissions 2.11 1.79 1.60 n/a 1.37 2.34 n/a
Pathology Consultant WTE per 1000 all admissions 1.88 0.98 2.92 n/a 2.60 2.00 n/a
Radiology Consultant WTE per 1000 all admissions 2.04 0.34 2.46 n/a 2.49 2.17 n/a
Ratio of outpatients to all admissions 4.08 3.55 5.15 n/a 4.64 4.70 n/a
* Whole-time equivalent (WTE)
n/a = not availableBMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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including hospital in-patient and out-patient systems;
radiotherapy; pathology; GPs, coroners; and chest clinics.
Linkage between cancer registration and death certificates
is achieved through the NHS Central Registry, which noti-
fies cancer registries of registered patients who die with
any diagnosis, and all patients with a cancer diagnosis.
Registries check hospital case-notes of patients, and are
estimated to include above 90% of patients with date of
diagnosis as well as date of death (both are needed to cal-
culate survival). The data may be analysed at sub-national
levels [12], but for the present study it was concluded that
data at cancer network level, with populations over 0.5
million, would be necessary to ensure statistical confi-
dence when using relative survival analysis. For a limited
group of individual level variables, including tumour
types and place of treatment, there is 95% completeness,
but lower figures for cancer stage. Table 9 shows relative
survival rates (ie adjusted for other 'background' mortal-
ity) for lung cancer in males and females.
National Cancer Patient Survey
This was a one-off survey of a sample of patients dis-
charged from NHS acute hospitals in England [13]. The
survey was undertaken by postal survey retrospectively in
2001, with reports from 56436 patients discharged
between July 1999 – June 2000. Sampling and surveying
were undertaken by an independent organisation, and the
data stored in Economic and Social Research Council
archive. The survey covered six cancers – breast, colorectal,
lung, non-Hodgkin lymphoma, and ovary prostate.
Response rates by trust were 60%-80%, while variables
have 5–19% missing data. The survey asked patients their
perspectives on care across the 'patient pathway': access to
care, waiting times, diagnostic process, first treatment,
hospital environment, outpatient experience. Table 10
shows a selection of these items for the Limited Data Set.
Data set characteristics
Three data sets (cancer registration/survival, HES, satisfac-
tion) are recorded for individual patients and three (wait-
ing times, Peer Review, Audit Commission) have data
aggregated at hospital trust level. (Individual patient sur-
vival and hospital episodes cannot be routinely linked by
the unique identifiers yet in England.) We could divide
most of the data sets according to the four most common
tumour types, breast, colo-rectal, lung and prostate can-
cers, which relate to the different natural survival patterns
and different management requirements described in the
national Manual of Cancer Services. Socio-economic posi-
tion can be estimated from three-digit postcodes for data
sets with individual records.
The data sets varied in size. Hospital Episode Statistics
record more than 12 million episodes each year and the
Table 2: Acute Hospital Portfolio indicators for hospitals in the network: Ward Statistics 2000/2001
Hospitals
Indicators A B C D E F G
Clinical nurse specialists (WTE) per 1000 FCE* n/a 2.20 0.87 0.32 0.80 0.65 0.50
Standardised ward patient accidents per 100 available beds n/a 202 59 26 115 66 119
All formal complaints per 1000 FCEs n/a 9.92 12.86 9.16 9.98 8.16 4.86
* Finished consultant episode (FCE)
Table 3: Acute Hospital Portfolio indicators for hospitals in the network: Radiology 2001/2002.
Hospitals
Indicators A B C D E F G
Waiting times* – mammography 5 n/a 2 0 1 n/a 2
Waiting times* – nuclear medicine 6 4 2 n/a 6 n/a n/a
Waiting times* – computer tomography 5 4 8 3 5 n/a 4
Waiting times* – magnetic resonance imaging 25 28 78 26 16 n/a 10
% exams unreported** 27 n/a 5 32 5 n/a 33
% exams reported by radiology staff 73 21 90 28 75 n/a 28
Inpatient exams per FCE 0.44 n/a 0.48 1.15 0.52 n/a 1.00
Outpatient exams per outpatient visit 0.25 n/a 0.23 1.23 0.29 n/a 1.33
Radiographers per 1000 FCE 0.71 n/a 0.71 1.24 0.73 n/a 1.48
*Average wait (median) in weeks
**Percentage of examinations unreported or reported by referring clinicians without agreement with radiology department
n/a = not availableBMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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Audit Commission collected over 100 items of data from
more than 200 trusts over a year. In contrast the Waiting
Times survey concentrates only on this dimension for the
same trusts. Only a few items were relevant from the large
data set within Hospital Episode Statistics, describing hos-
pital activity. The Audit Commission hospital data pro-
vided an array of general characteristics: a subset was
chosen which was more particularly related to cancer
(although not separated by tumour type). The Peer
Review data were treated as binary (compliant or not com-
pliant with the standard), and were summed to give total
scores. The National Cancer Satisfaction Survey items had
been chosen by an earlier factor analysis into nine themes
each represented by one lead question, while five inde-
pendent questions for one theme were averaged [13].
Presentation
Where available, cancer service indicators can be pre-
sented with a mean and confidence interval, customarily
set at 95%, as a snap-shot (cross sectional) or time related
(longitudinal). Both may be presented in the presence or
absence of a meaningful and appropriate comparator.
Cross sectional
Figure 1 utilises the first approach and shows a funnel plot
of an item from the patient satisfaction survey: each point
is a trust. The plot takes into account the different sample
sizes in each survey to indicate the normal confidence
interval, and identifies outliers. It represents a snap-shot
and contains data values that can be compared.
Alternatively, points and confidence intervals can be
arrayed individually against the group average, as shown
in Figure 2 representing cancer survival at cancer network
level, grouped by regions. This also represents a snap-shot
and contains data values that can be compared.
Lastly, the cancer indicators can be used together for com-
parisons: Figure 3 shows a spider plot of rankings for an
item in each of the five data for a single network: best
comparative performance would cover the least surface
area, worst performance would cover the greatest area.
This also represents a snap-shot but does not contain data
values that can be compared – it is therefore a profile.
Although this presentation does not show confidence
intervals, the representation on a single plot of different
dimensions allows visual assessment of relative closeness
to stronger or weaker performance.
Longitudinal
For monitoring, data can be used to review performance
over time. Figure 4 shows a moving average control chart
Table 4: Acute Hospital Portfolio indicators for hospitals in the network: Medicines Expenditure 2001/2002.
Hospitals
Indicators A B C D E F G
BNF* Spend malignant disease (£000) n/a* 472 1620 2507 469 297 1963
BNF* Spend malignant disease per FCE** (£) n/a 21.59 40.38 28.60 10.67 8.46 32.44
*British National Formulary (BNF)
Table 5: Cancer Standards Peer Review indicators for hospitals in the network: number of standards achieved by themes
Themes Total number of standards Hospitals
AB CDE
Patient-centred care 5 10 223
Breast cancer MDT* 39 26.5 25 22 19 27
Colorectal cancer MDT* 35 23 19 15 23 24
Lung cancer MDT* 36 14 25 24 18 22
Pathology 7 43 544
Non-surgical oncology 5 1 . 5 1 000
Radiotherapy 60 (no service) 45 52 (no service) 59
Chemotherapy 45 21.5 30 33 37 34
Palliative care 11 86 1 1 77
Education 2 00 000
Communication 3 1 . 5 0 202
Cancer units (centres) 15 (16) 71 0 01 20
* Multi-disciplinary team (MDT)BMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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for cancer waiting times, with an expected trend and con-
fidence intervals, based on the first year and a half, and
with later observations moving strongly outside the pro-
jection.
Discussion
Health service management decisions deserve to made
with a full perspective of structural, process and outcome
information. In the UK, cancer, uniquely as a disease
group, has population incidence and outcome (survival)
data available through cancer registers. Our study shows
that other indicators can be drawn from data sets, describ-
ing hospital level characteristics, and the indicators can be
presented together for management and comparative uses
by cancer networks. While this study is theoretical, as
these data are not at present being used together in this
way in England, it demonstrates the potential for use in
cancer service performance management at system level.
Indicators
The NHS Cancer Plan [3] created a new organisational
structure, the cancer networks, with a managerial objec-
tive of improving cancer care. While information for man-
agement was part of the original cancer strategy, we are
not aware of any guidance provided to cancer networks
for using information in quality improvement. Our study
has identified cancer data sets that, with varying dimen-
sions, can contribute to an assessment of service quality.
Health care indicators have been developed in England to
illustrate variations in practice and outcomes, for example
the Healthcare Commission's performance ratings [14].
We identified six datasets from routine sources in England
that reflect contemporary recommendations for broad-
based indicators of quality [15,16]. Of the six data sets we
identified, three (Hospital Episode Statistics, Waiting
Times and cancer survival) are continuously collected,
and collection of the Peer Review and Acute Hospitals
Portfolio datasets is being repeated. The National Cancer
Satisfaction Survey was only undertaken in full once, in
2000/2001, but there are now annual surveys of hospital
patients, by Trusts in England, undertaken by the Health-
care Commission from which data on cancer patients
could be drawn.
As NHS datasets are primarily collected for national rather
than local use, there must be caution in using them in dis-
aggregated form. For example, Rachet et al [12] consider
that one and five year survival divided by tumour type and
Table 6: Cancer Standards Peer Review indicators for hospitals in the network: breast cancer multi-disciplinary team service standards 
– number of standards complied with.
Topic Total number of standards Hospitals
AB C D E
MDT structure 9 97 5 6 7
MDT meetings 4 1.5 3 1 2 3
Operational policies 13 6.5 7 8 7 8
Patient centred care 5 31 0 1 2
Treatment 1 11 1 0 1
Clinical guidelines 1 11 1 1 1
Referal guidelines 1 11 1 1 1
Data collection 2 22 2 0 2
Network audit 1 00 1 0 0
Clinical trials 1 0.5 1 1 1 1
MDT workload 1 11 1 0 1
* Multi-disciplinary team (MDT
Table 7: Hospital Episode Statistics indicators for hospitals in the network: colorectal cancers
Indicators Hospitals
AB CD EF
Number of patients 207 247 152 209 107 210
In-hospital mortality 13.5% 7.3% 9.9% 11.5% 16.8% 7.6%
Mean number of episodes per patient 1.2 6.1 1.6 6.5 5.1 3.4
Mean length of stay (days) 15.5 8.5 21.2 8.2 11.3 10.2
Median length of stay (days) 10 0 11 1 8 2
Mean waiting time (days)* 40.2 15.0 20.2 24.3 9.3 15.4BMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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sex should not be presented as an indicator at the level of
primary care organisation because of small numbers;
however, at SHA level, and cancer network, these data can
be presented with confidence intervals. Equally, the
National Cancer Services Analysis Team [17] suggest that
publication of Hospital Episode Statistics should be lim-
ited to Health Authority (and thus cancer network) level,
on grounds of patient confidentiality, while more detailed
analysis should be kept within the health service.
There is some overlap between the data sets: for example,
cancer waiting times that are collected specially by Trusts
refer to patients urgently referred for assessment by GPs,
while hospital admissions data from Hospital Episode
Statistics include all cancer patients admitted from a wait-
ing list. These will, therefore, have slightly different mean-
ing for management purposes. There are also different
denominator populations: trusts serve catchment popula-
tions rather than geographical populations, and cancer
networks are designed to reflect cooperation patterns
between hospitals rather than strict administrative bound-
aries.
The use of cancer services indicators differs between stake-
holders. The first use should be for staff who are providing
the services – to understand it in aggregate, to see trends
and to compare with others. This can lead to collective
management decisions to address weaknesses suggested
by the indicators, which may include further investigation
and changes practice or provision. Within a managed sys-
tem which is publicly accountable, such as the NHS, indi-
cators can also be of use in monitoring – both identifying
trends and assessing performance. The public are also
potential users of such information, for example, in mak-
ing choices between providers, although patients may be
interested in information at a level of detail in relation to
their own condition that is not available from routine
aggregate indicators. A final set of stakeholders is the
research community, since associations of data items
between data sets may be used for explanatory studies of
organisational determinants of care outcomes.
Presentation
Indicators can enable public health practitioners, working
alongside clinicians and managers, to assess the effective-
ness and efficiency of services in improving population
health. Flowers et al [18] have proposed '20 questions to
ask a proposed public health indicator'. Bird et al [19]
describe issues to increase the rigour of performance mon-
itoring, and to limit inappropriate inferences. Equally,
Spiegelhalter [20] has been concerned to ensure interpre-
tation that fully recognises statistical variation.
The graphs present comparative data for cancer networks.
The Department of Health has presented 'performance
indicators' grouped the large number of hospitals into
clusters (by size, teaching status, specialty etc) so as better
to compare 'like with like'. It is also possible to set a finite
level as an optimum 'target' for comparisons. However,
there were fewer cancer networks than hospitals for us to
compare, and we had no particular criteria to group as
similarities or expected levels to set as targets.
Table 8: Cancer Waiting Times indicators for hospitals in the network: lower gastro-intestinal tumours. Percentage of urgent GP 
referrals seen within 2 weeks (numbers of referrals in brackets)
Tumour Hospitals
Year A B C D E F
Lower gastrointestinal** 2001/2* 98.1% (441)1 0 0 %  ( 90)9 7 . 8 %  ( 47)8 9 . 7 %  ( 156)9 4 . 6 %  ( 75) 97.5% (40)
Lower gastrointestinal** 2002/3 89.9% (525)9 8 . 1 %  ( 110)1 0 0 %  ( 122)8 7 . 3 %  ( 197) 88.0% (201)9 7 . 3 %  ( 114)
Lower gastrointestinal** 2003/4 100% (441)1 0 0 %  ( 157)9 8 . 3 %  ( 186)9 9 . 6 %  ( 271) 97.7% (177)1 0 0 %  ( 184)
*data includet only urgent referrals received within 24 hours
**ICD-10 codes C17-21 and C26
Table 9: Cancer Registry on survival (available only at network level). Age standardised relative survival estimates for patients 
diagnosed in 1996–2001 and followed-up till 31 December 2003
Lung cancer Sex Cancer cases Survival period Relative survival, % 95% Confidence interval
male 1749 one-year 25.9 23.8
female 1096 one-year 30.0 27.1
all 2845 one-year 27.4 25.7
male 1749 five-year 7.0 5.6
female 1096 five-year 7.4 5.5
all 2845 five-year 7.1 5.9BMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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Graphical methods of presentation help interpretation of
statistical variation. Funnel plots are particularly relevant
for presenting the satisfaction data, as they indicate critical
differences in sample size. Caterpillar plots are more
sophisticated than standard league tables, providing rele-
vant comparisons, eg grouping by socio-economic charac-
teristics or standardised by local populations. The control
chart is a valuable method for assessing local trends in
relation to specific management objectives. Spider-web
diagrams allow easy comparisons across multiple dimen-
sions, which is relevant for performance measurement.
Quality monitoring
Performance indicators have developed because of greater
availability of quantitative data, and can contribute to
improving health care quality [16,18]. However, Freeman
& Walshe [21] and Lilford et al [15] contrast use for exter-
nal performance review with internal use for quality
improvement. Hierarchical managers, for example gov-
ernment ministries, are interested in how health-care pro-
viders compare with each other and whether they are
collectively achieving goals. Service providers are more
interested in assessing how well they are performing and
moving towards their own management goals.
There is broad agreement that measures of quality should
be based on a collection of indicators rather than a single
item or 'league table': a collection of indicators (some-
times called a 'scorecard') can better describe quality and
provide different dimensions for each service to prioritise.
Focussing on a limited number of targets may also
encourage gaming.
Lilford et al [15] describe a range of studies linking quality
of clinical care with outcomes, across various specialties
and services, and conclude that the relationship is often
weak or indeed non-existent. They propose that 'compar-
ative outcome data should not be used by external agents
to make judgments about the quality of hospital care'.
Instead, they recommend that clinical services should
'monitor their own performance (process and outcome),
compare themselves with others or their own past per-
Percentage of patients reporting 'a problem with amount of  respect and dignity' in the National Cancer Patient Survey Figure 1
Percentage of patients reporting 'a problem with 
amount of respect and dignity' in the National Can-
cer Patient Survey. Values for trusts in one network
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Table 10: Indicators from the National Survey of Cancer Patients for hospitals in the network. Prostate cancer: % respondents 
expressing a problem with each aspect of care.
Question Hospitals
ABCDEF
Number of patients responding to different questions (range) 41 – 58 2 – 13 22 – 40 22 – 89 9 – 20 20 – 44
Enough nurses on duty (a3) 20.6% 0.0% 27.5% 22.4% 21.0% 25.0%
Date of first hospital visit ever cancelled or postponed (b1) 11.1% 7.6% 14.7% 11.2% 25.0% 26.9% *
Treated with respect and dignity (b7) 21.2% 46.1% * 36.3% * 20.3% 26.3% 25.0%
Purpose of treatment discussed (b19 17.0% 38.4% 29.4% 23.4% 26.3% 14.8%
Consent form signed (b21) 20.4% 15.3% 0.0% * 25.3% 10.0% 15.3%
Pain and discomfort (b24) 59.5% 76.9% 81.8% * 65.0% 85.0% * 71.4%
Enough time explaining what would happen after discharge (c1) 18.6% 23.0% 36.3% 26.9% 36.8% 29.6%
Written or printed information given (c2) 36.3% 53.8% 48.4% 38.0% 36.8% 22.2%
Waiting time from GP visit till first hospital appointment (d3) 50.0% 50.0% 40.9% 61.7% 50.0% 55.0%
Being told what was wrong (d10) 1.8% 0.0% 6.6% 2.3% 5.8% 0.0%
Time spent telling what was wrong (d15) 33.9% 66.6% 32.2% 29.5% 33.3% 26.0%
Outpatient appointment ever cancelled or postponed by hospital (e4) 26.8% 16.6% 10.0% 14.8% 30.0% 24.3%
Waiting after appointment time to see a doctor (e6) 43.9% 33.3% 51.7% * 43.4% 33.3% 39.0%
Time spent by doctor during appointment (e7) 26.1% 0.0% 27.5% 22.7% 22.2% 26.8%
Whether time spent by doctor was enough (e8) 4.7% 16.6% 20.6% * 0.0% 11.1% 7.3%
Confidence and trust in doctor (e9) 0.0% 0.0% 6.8% 0.0% 11.1% 7.3%
Privacy (e11) 0.0% 0.0% 6.8% * 0.0% 0.0% 0.0%
Treated with respect and dignity (e13) 0.0% 0.0% 3.4% 0.0% 0.0% 0.0%
* Trusts significantly different from national average (p < 0.05)BMC Health Services Research 2008, 8:45 http://www.biomedcentral.com/1472-6963/8/45
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formance as appropriate, and take whatever action seems
necessary'. For example, in a study in another clinical
field, acute myocardial infarction, heart failure, and pneu-
monia hospital performance was improved through quar-
terly monitoring and feedback of standardized measures
[22]. However, Lilford et al [15] also conclude that the lit-
erature shows stronger associations between clinical out-
comes and organizational factors, including availability of
equipment, staffing levels, management processes and
staff communication. As decisions on resources may be
made externally, for example by a higher-level tier, infor-
mation from the data sets will need to be interpreted
jointly between internal and external managers.
An intermediate use for indicators, between external mon-
itoring and internal quality improvement, is in describing
needs and trajectories for managers who are making
investment decisions and who are accountable for popu-
lation outcomes. The primary focus for information strat-
egy in the NHS is the National Programme for IT
('Connecting for Health'), which seeks to link over 30,000
GPs in England with almost 300 hospitals, and give
patients access to their personal health and care informa-
tion. Nevertheless, this is a complex task, and the chang-
ing technology and fragmentation of providers (across
such a large organisation as the NHS) provide many chal-
lenges to implementation.
Spider-chart ranking of one network for one dimension in  each of five data sets for breast cancer (each dimension: 0 =  most favourable, 10 = least favourable) Figure 3
Spider-chart ranking of one network for one dimen-
sion in each of five data sets for breast cancer (each 
dimension: 0 = most favourable, 10 = least favoura-
ble). A: 1-year relative survival. B: Satisfaction survey 
'respect and dignity'. C: Compliance with cancer standards. 
D: % GP urgent referrals seen within 2 weeks. E: Inhospital 
mortality.
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Breast cancer, age standardised five-year % relative survival (with CIs and national and regional averages) by cancer networks in  England, grouped by NHS regions, of women with breast cancer diagnosed 1996–2001, followed up to 31 December 2003 Figure 2
Breast cancer, age standardised five-year % relative survival (with CIs and national and regional averages) by 
cancer networks in England, grouped by NHS regions, of women with breast cancer diagnosed 1996–2001, fol-
lowed up to 31 December 2003
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Improving cancer information
Cancer networks are a new approach to improving cancer
services, based on the concept of coordination and devel-
opment rather than hierarchical 'command' management.
Their practice conforms with the findings of Leggat [23]
that 'improving practice within hospitals ... the three most
important aspects being the development of teamwork,
performance management and sophisticated training'.
Evaluations [24,25] suggest that cancer networks are
developing successfully, but there are variations in the
perceptions of need for, and use of, information for their
work.
The National Health Service has a mixed track record in
developing information systems [26]. It is a considerable
challenge, because of the myriad of fields from which data
can be recorded, and the variety of end-users. Moreover,
the requirements of confidentiality, changing technology
and market-led implementation have constrained free
data exchange. But existing data sets about cancer services
can be of use for local providers, monitoring and commis-
sioning authorities, patients and researchers. Availability
to users can be facilitated through the NHS National Pro-
gramme for IT 'Connecting for Health'. However, this will
require positive action by the Department of Health, as at
present there are few incentives for networks to use or dis-
seminate comparative aggregate data.
We might also envisage a geographically wider use of can-
cer data sets. In the USA, the National Cancer Institute has
recognised the potential of 'cancer performance measures'
to 'inform health policy and monitor cancer disparities
and disease burden' at the macro-level [27].
In Europe, the EUROCARE study [28], showing the rela-
tively poorer survival of cancer patients in Britain com-
pared with European neighbours, was a trigger for the
reorganisation of services in England and Wales in 1995.
Another study, the European cancer health indicators
project [29] has, within five fields of indicators, one on
'treatment & clinical aspects', suggesting that international
indicators should include delay in cancer treatment (pilot
studies), provision of radiotherapy and CT equipment,
compliance with best oncology practice and percentage
patients receiving palliative radiotherapy. While interna-
tional comparisons must give attention to country differ-
ences in definitions and standards, indicators may also
assist in understanding the relationship between the
organisation of cancer services and differences in survival
across Europe.
Conclusion
The study has identified six contrasting datasets available
to the National Health Service in England from which
indicators can be drawn describing structure, process and
outcomes for cancer services. At present, these indicators
Moving average control chart Figure 4
Moving average control chart. Percentage GP urgent referrals for lung cancer seen within 2 weeks, single NHS 
hospital, data for consecutive year quarters 2001/2 – 2003/4. % seen within 2 weeks. Moving average. Control limits for 
moving average
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are not used together dynamically for comparisons or
management by cancer networks, but the study demon-
strates their potential for integrated use at system level.
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